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Abstract
Background: Interleukin-8 (IL-8, CXCL8) is readily produced by human malignant cells. Dendritic cells (DC) both produce IL-8
and express the IL-8 functional receptors CXCR1 and CXCR2. Most human colon carcinomas produce IL-8. IL-8 importance in
malignancies has been ascribed to angiogeneis promotion.
Principal Findings: IL-8 effects on human monocyte-derived DC biology were explored upon DC exposure to recombinant
IL-8 and with the help of an IL-8 neutralizing mAb. In vivo experiments were performed in immunodeficient mice
xenografted with IL-8-producing human colon carcinomas and comparatively with cell lines that do not produce IL-8.
Allogenic T lymphocyte stimulation by DC was explored under the influence of IL-8. DC and neutrophil chemotaxis were
measured by transwell-migration assays. Sera from tumor-xenografted mice contained increasing concentrations of IL-8 as
the tumors progress. IL-8 production by carcinoma cells can be modulated by low doses of cyclophosphamide at the
transcription level. If human DC are injected into HT29 or CaCo2 xenografted tumors, DC are retained intratumorally in an IL-
8-dependent fashion. However, IL-8 did not modify the ability of DC to stimulate T cells. Interestingly, pre-exposure of DC to
IL-8 desensitizes such cells for IL-8-mediated in vitro or in vivo chemoattraction. Thereby DC become disoriented to
subsequently follow IL-8 chemotactic gradients towards malignant or inflamed tissue.
Conclusions: IL-8 as produced by carcinoma cells changes DC migration cues, without directly interfering with DC-mediated
T-cell stimulation.
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Introduction
In a previous study [1] we showed that
111Indium-labeled DC
when injected into tumor lesions of patients suffering advanced
digestive carcinomas [2] tended to remain inside the injected
lesion. An explanation for such a retention was proposed in the
sense that the human tumors abundantly produce IL-8 [1,3] and
DC express CXCR1 and CXCR2 functional IL-8 receptors on
their plasma membrane [1,4,5]. However, no definitive proof was
provided for the role of IL-8 in intratumoral retention of DC [1].
An IL-8 homologue is absent from the mouse genome and these
precludes incisive definitive genetic experimentation on the role of
IL-8 in murine tumor models. However there are reports
suggesting that mouse CXCR1 is activated by human IL-8, hence
permitting to some extent experiments in xenografts [6].
Chemokine receptors guide DC in physiology and in inflam-
mation [7,8]. DC migration from inflamed/infected [9] or
malignant tissues [10,11] is important for the orchestration of
immune responses. Chemokine receptors do not only regulate
motility but also control other cellular functions such as activation
or survival in various cell types [11,12]. Therefore it would not be
a surprise if the chemokine microenvironment modified DC
functions other than migration [12].
Human tumor cells produce IL-8 in most cases [1,13] as a
biological dirty trick played by the malignant tissue to promote
angiogenesis [3,13,14,15] and possibly to support the type of
smoldering inflammation that promotes tumor progression and
metastasis [14,16,17]. Tumor growth in human patients statisti-
cally correlates with IL-8 serum concentrations [3,18]. Recently, a
role for IL-8 has been described in the resistance to antiangiogenic
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from sunitinib can be thwarted by co-treatment with neutralizing
anti-IL8 mAb [19].
IL-8 was originally discovered as a powerful attractor of
polymorphonuclear leukocytes (PMNs) [20,21] in acute inflam-
mation [21], but may act on other leukocyte subtypes [1,22] and
on endothelial cells [15]. In turn, DC are both responsive to IL-8
[4,5], and produce IL-8 either when inactive or more overtly so,
when activated/matured [1]. Injecting DC inside tumors has been
intended to enhance antitumor activity for therapeutic purposes in
animal models [11,23] and in the clinic [2,24,25]. One of the
hurdles faced is that the tumor microenvironment is rich in
substances impairing DC functions [11,26]. DC migration into
lymph nodes is of critical importance in cancer immunotherapy
based on DC [27,28,29]. If retained intratumorally, DC would be
prey for tumor microenvironmental factors such as TGF-b for
longer periods of time [11], thereby causing damage to the
induction of anti-tumor immunity.
Here we show that xenografts of human tumors retain DC
inside the injected tumors by means of IL-8-mediated chemoat-
traction, that can also recruit DC to the malignancy when injected
in the subcutaneous connective tissue in the vicinity of the tumor.
However, the same functional recombinant IL-8 that attracts DC
and PMNs does not impair the abilities of DC to induce T-cell
activation and proliferation either in vitro or in vivo. Interestingly,
pre-exposure of DC to IL-8 restrains subsequent migration
towards IL-8 chemo-attractive gradients indicating desensitization
of the receptors.
Methods
Ethics statement
Animal studies have been performed in accordance with
Spanish legislation under specific approval from the institutional
ethics board by the Comite ´d eE ´tica para la Experimentacio ´n Animal of the
University of Navarra (Study 03/007 approval). Human cells are
obtained from Blood donors (public blood bank of Navarra) under
written informed consent for research.
Dendritic cell generation
Dendritic cells were generated from filter buffy coats (FBC)-
derived monocytes donated by healthy donors [30] who explicitly
sign a written informed consent. To generate immature DCs from
monocytes, human peripheral blood was isolated by Ficoll-Paque
gradient centrifugation from FBC. Isolated mononuclear cells
from these sources were subjected to positive selection using anti-
CD14-conjugated paramagnetic beads and purified using the
AutoMacs system according to the manufacturer’s instructions
(Miltenyi Biotec, Bergisch Gladbach, Germany). Purified mono-
cytes were cultured for 7 days in RPMI-1640 with 5% (v/v) heat
inactivated FCS. To differentiate dendritic cells from CD14
+ cells,
culture medium was supplemented with GM-CSF (1000 U/mL;
Novartis, Basel, Switzerland) and IL-4 (500 U/mL; R&D Systems,
Minneapolis, MN). DCs were matured adding clinical grade TNF-
a (50 ng/mL; Boehringer Ingelheim, Ingelheim, Germany), IFN-a
(1,000 IU/mL; Schering-Plough, Kenilworth, NJ) and Poly I:C
(10 mg/mL; Ampligen, Bioclones, Tokai, South Africa) for 48 h.
Cell lines and IL-8 concentrations in mouse serum and
culture supernatants
HT29, CaCo2 and SW48 colon carcinoma cell lines were
obtained from American Type Culture Collection (Rockville,
MD). Cell lines were cloned by limiting dilution in 96-well plates
and subcultures (10
5 cells) were tested for the concentration of IL-8
in the 24 h supernatants from these subcultures by means of
ELISA (BD Biosciences, San Diego, CA). Cyclophosphamide
(Cytoxan) was purchased in our hospital pharmacy.
Semiquantitative RT-PCR for IL-8
Total cellular RNA was extracted with Trizol (Invitrogen,
Carlsbad, CA) according to the protocol provided by the
manufacturer. First-strand cDNA was synthesized from 1 mg total
cellular RNA using an RNA PCR kit (Takara Bio Inc., Otsu,
Japan) with random primers. Thereafter, cDNA was amplified
using 30, and 28 cycles for IL-8 and for b-actin, respectively. The
specific primers used were as follows: IL-8, forward primer 59-
ATGACTTCCAAGCTGGCCGTG -39 and reverse primer 59-
TTATGAATTCTCAGCCCTCTTCAAAAACTTCTC-39; and
for b-actin, forward primer 59-GTGGGGCGCCCCAGG-
CACCA-39 and reverse primer 59-CTCCTTAATGTCACG-
CACGATTTC-39. The product sizes were 300 bp for IL-8, and
548 bp for b-actin. The thermocycling conditions for the targets
were as follows: denaturing at 94uC for 30 s for IL-8, and b-actin,
annealing at 60uC for 30 s for IL-8 and b-actin, and extension at
72uC for 90 s for IL-8 and b-actin. The PCR products were
fractionated on 2% agarose gels and visualized by ethidium
bromide staining. The quantity of a band was measured by the
area under its intensity profile curve using BioRad Quantity One
1-D Analysis Software (Bio-Rad Laboratories, Hercules, CA,
USA). b-actin was employed to normalize the amount of RNA
used in each reaction.
Mouse tumors
Nude mice, Rag
2/2 or Rag
2/2 IL-2Rc
2/2 were obtained
from The Jackson Laboratory. Animal experiments were in
accordance to Spanish laws and approval was obtained from the
animal experimentation committee of the University of Navarra
(Study 03/007 approval). These mice were injected with the tumor
cell lines HT29 (5610
6 cells), CaCo2 (10
7 cells) or SW48 (5610
6)
to induce subcutaneous tumors. IL-8 in serum samples was
sequentially measured by ELISA (BD Biosciences). When
indicated 3 mg/mouse of cyclophosphamide were injected i.p.
In vivo migration
Female nude mice, Rag
2/2 or Rag
2/2 IL-2Rc
2/2 as
indicated, were subcutaneously injected with 5610
6 HT29
(n=4), 10610
6 CaCo2 (n=4) or 10
6 SW48 (n=3) tumor cells.
When tumors reached about 1 cm diameter, 10
6 mature DCs
were labelled with 2.5 mM CFSE (Sigma, Barcelona, Spain) or
4610
26 M PKH26 (Sigma), washed and injected intratumorally.
Mouse IgG (100 mg, BD Pharmingen) or neutralizing anti-human
IL-8 mAb (100 mg, BD Pharmingen) were coinjected within the
same syringe into the tumors. In case of HT29 and SW48, cell
suspensions from the tumors were generated with the GentleMacs
dissociator device (Miltenyi Biotec). Cell suspensions were
analysed by FACS and fluorescent cells counted. In the case of
CaCo2 xenografts, three days later, tumors were mechanically
homogenized. Tissue homogenates were cleared from debris by
centrifugation and fluorescence was measured using a plate
fluorimeter (Polarstar Galaxy, BMG). Migration was calculated
as fluorescence in the tumor divided by total input fluorescence
injected (fluorescence was quantified in arbitrary units).
Cytokine production by maturing DC
For in vitro stimulations, 10
5 DC were cultured 48 h with
medium alone (control), LPS (1 mg/mL) purchased from Sigma,
R-848 imidazoquinoline (1 mM) purchased from Pharmatech
Malignant Cell-Derived IL-8 Effects on DC
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Abnova (Taipei, Taiwan). After culture for 48 h, supernatants
were collected and the cytokine concentration was determined by
immunoassay. Commercially available ELISA kits were used for
the detection of IL-12p70 and IL-10 (BD Bioscience).
FACS analysis
FITC and PE-labeled mAb specific for the DC maturation
markers: CD80, CD83, CD86 and HLA-DR (BD Bioscience) and
isotype-matched labeled controls were used to characterize cell
surface phenotypes by flow cytometry. Dendritic cells (10
5) were
washed in cold PBS and incubated 15 min at 4uC with specific
FITC or PE-labeled Abs. MAbs against IL-8 receptors (CXCR1
and CXCR2) were used by indirect fluorescence developed with a
rabbit anti-mouse antiserum tagged with FITC (Jackson Immu-
noResearch Labs, West Grove, PA).
In vitro and in vivo MLR
In vitro MLR were performed as described [26]. Briefly, a total
of 2610
5 lymphocytes from a distinct donor were added on day 9
at different T cell:DC ratios (1280:1, 640:1, 320:1, 160:1, 80:1 and
40:1). After 3 days, the [methyl-3H]thymidine uptake was
determined by the addition of 1 mCi of [methyl-3H]thymidine.
Female Rag
2/2 IL-2Rc
2/2 were subcutaneously injected with
5610
6 HT29 cells. When tumors reached approximately 1 cm in
diameter, these mice and tumor-free mice were intraperitoneally
injected with 1610
6 DC and 5610
6 PKH2-labeled PBLs. After 4
days, cells were obtained by intraperitoneal lavages and samples
were analysed using a FACSCalibur Flow Cytometer (Becton
Dickinson). The number of T cell divisions is proportional to the
dilution of PKH2 intensity and was found to be negligible in the
absence of DC (data not shown). For FACS analysis lymphocytes
were gated based on FSC/SSC features.
PMN purification and fluorescence labelling
In vitro neutrophil and DC migration was measured in Transwell
Chambers (5 mm; Corning Costar, Corning, NY). PMN cells were
enriched by sedimentation of peripheral blood mixed in a dextran
(6% v/v) solution. After sedimentation, floating fractions were
collected. Red cells in the resuspended pellets were osmotically
lysed. The remaining cell suspensions were layered onto Ficoll-
Paque gradients and pellets were collected and washed after
centrifugation. Neutrophil purity was .95% (CD15
bright neutro-
phils)
In vitro chemotaxis assay
In vitro neutrophil and DC migration was measured in Transwell
Chambers (5 mm; Corning Costar, Corning, NY). Both PKH26-
DCs (10
5) and PKH2-labeled neutrophils (10
5) or only PKH2-
labeled neutrophils were added to the upper chamber and
migration stimuli were placed in the lower chamber. In this
experiment IL-8 (R&D Systems) was used at 20 ng/mL as positive
control. In other cases PKH26-DCs with or without IL-8
neutralizing mAb or IgG as control (BD Pharmigen) at 20 mg/
mL was placed in the lower chamber as indicated. Transmigrated
cells in the lower chamber were quantified using a FACSCalibur
flow cytometer (BD Biosciences) or fluorescence microscopy
imaging of the lower chamber. In some cases the lower chamber
contained a subconfluent monolayer of HT29 cells. The
chemotactic index was calculated as the number of migrated cells
in the experimental conditions divided by number of migrated
cells in the negative control, which is complete culture medium. In
the experiments with HT29 cell in the lower chamber number of
PKH2-fluorescent DC per microscopic field (620) in the lower
chamber were quantitated in triplicate wells by a blinded observer.
Recombinant MIP3a was from R&D.
Statistics
Comparisons were made with paired student’s t tests. Values of
p are given in the corresponding experiments.
Results
HT29 and CaCo2 tumor cell lines xenografted into
immunodeficient mice generate tumors that produce
IL-8
A panel of human colon carcinomas was tested in order to
identify cultures that produce high amounts of IL-8 to the
supernatant [1]. All clonal subcultures of HT29 showed high
homogeneous outputs of IL-8 while the SW48 cell line did not
reach detectable levels in any experiment, and CaCo2 subcultures
showed around one half of the production when compared to the
levels attained by HT29 cells cultured at identical density for the
same period of time (Figure S1). Microenvironment conditions
and therapy may modify the ability of tumor cells to produce IL-8.
Figure 1A shows that the production of IL-8 secreted to culture
supernatants by viable HT29 cells was reduced in 24 h by
exposure to low concentrations cyclophosphamide, while cells still
preserved membrane integrity (.90% viability by trypan blue
exclusion). Interestingly, the low range of cyclophosphamide
concentrations was more effective at preventing IL-8 bioproduc-
tion and secretion to the supernatant. Gemcitabine and radiation
did not or more weakly affected IL-8 secretion (Figure 1A and data
not shown). Moreover, in a repeated set of experiments
semiquantitative RT-PCR for IL-8 in comparison with the house
keeping mRNA b-actin showed that cyclophosphamide inhibits
IL-8 production at the mRNA level in a dose-dependent manner
(Figure 1B), in such a way that low dose cyclophosphamide was
better at mediating this effect than higher concentrations.
These results open the possibility that IL-8 production can be
acutely reduced by cyclophosphamide for therapeutic purposes.
Indeed, metronomic cyclophosphamide is becoming an attractive
alternative for cancer management [31] and potentiation of a
variety of immunotherapies [32].
When HT29 was xenografted in athymic nude mice, it gave rise
to subcutaneous nodules that grew steadily over time (Figure 1C).
Sequential sera samples from such animals contained increasing
concentrations of IL-8 (Figure 1C) that correlated with tumor
progression as reported in human patients [3].
CaCo2 failed to graft as subcutaneous nodules in two thirds of
cases (data not shown), but grafted homogeneously as multiple
peritoneal nodules if injected intraperitoneally (Figure S2). CaCo2-
grafted animals also showed circulating IL-8 (Figure S2) but at
lower concentrations if compared to HT29-bearing mice, as
expected from the productions of IL-8 in the cell line cultures.
Apart from this quantitative difference, the tendency was similar in
tumors from both cell lines.
Importantly, treatment of mice with a single dose of 3 mg/mouse
of cyclophosphamide reduced the serum concentration of IL-8 in
the next 24 h in a range from 48 to 100% (Figure 1D), while those
concentrations rapidly rebound in 48–72 h. It is of note that for this
experiment mice with 7-day palpable tumor xenografts were used,
so the concentrations of IL-8 in plasma were still low.
In conclusion, xenografted colon carcinomas retain the property
of producing high amounts of human IL-8, and our results
indicate that such a function could be modified by cyclophospha-
mide.
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HT29 tumors are retained by IL-8 in the tumor
microenvironment
In order to study whether IL-8-producing tumors would retain
intratumorally DC injected inside the lesion, we first chose the
HT29 xenografts because of their higher bioproduction of IL-8.
Human DC were derived from CD14
+ monocytes in the presence
of GM-CSF and IL-4 and labeled with PKH26. Fluorescent DC
were injected into HT29 tumor nodules subcutaneously implanted
into Rag
2/2 IL-2Rc
2/2 mice. In some of the mice, DC were
injected with control polyclonal mouse IgG antibody, while in other
cases were resuspended with 100 mg/mL of an anti-human IL-8
neutralizing mAb. 72 h after DC injection, tumors were removed
anda single cellsuspension was generated. The number offluorescent
human CD11c
+ cells versus total cells was quantified. As can be seen
in figure 2A, IL-8 indeed retained DC intratumorally since the
neutralizing anti-IL-8 mAb decreased the number of cells that
remained inside the tumor by more than one half (Figure 2A). FACS
analysis representing two cases are shown in figure 2B as an example.
These results were confirmed in athymic nude mice bearing
subcutaneous CaCo-2 tumors (Figure S3) indicating that the
phenomenon was not exclusive of HT29-derived tumors.
SW48 cells, that failed to produce IL-8 as shown in figure S1,
were xenografted in Rag
2/2 mice. In this case, the tumors could
not retain DC labeled with the fluorescent dye PKH26. Figure 2C
shows representative dot plots from three mice 72 h post
intratumoral injection along with the fluorescence of input DC
(left dot-plot of figure 2C). These results on the colon cancer cell
line that does not produce IL-8 further indicate that this
chemokine was important for the retention of DC inside the
tumor upon intratumoral release.
Lack of IL-8 effects on DC-mediated T-cell stimulation
Functional response to IL-8 involves signalling pathways that
might alter DC functions, since these cells are known to express
CXCR1 and CXCR2 [1]. We explored this question in detail
Figure 1. HT29 cells when xenografted secrete IL-8 to the plasma of the mice. ELISA determination of IL-8 in the supernatant of HT29
confluent cultures in the presence of indicated concentrations of cyclophosphamide (1000 to 0.001 mg/mL), or gemcitabine (1000 to 0.1 mg/mL)
during the 24 h prior to supernatant collection. When indicated the solution vehicle of both drugs was added at the highest concentration. Results
represent mean6SEM from three experiments. (B) Separate set of experiments as in A but in this case HT29 were collected and IL-8 mRNA was
quantified by RT-PCR. PCR bands are shown in the upper panel and densitometry quantitative data given in the lower panel representing relative
expression of IL-8 mRNA in comparison with b-actin mRNA. (C) Subcutaneously xenografted HT29 cells in Rag
2/2 IL-2Rc
2/2 mice gave rise to
progressing tumors (left axis depicting mean tumor diameter) and increasing serial serum concentrations of human IL-8 (right axis). Results represent
mean6SEM of three independent experiments with 6 mice per experiment. Similar results were observed with CaCo2 tumors xenografted in the
peritoneal cavity (Figure S1). (D) IL-8 serum concentrations of three individual Rag
2/2 IL-2Rc
2/2 mice bearing HT29 tumors for seven days before a
single intraperitoneal injection of 3 mg of cyclophosphamide and 24 and 48 h after treatment. The percentages of reduction at 24 h are indicated.
Experiments were repeated at least three times with the exception of (D) that was performed with three individual animals.
doi:10.1371/journal.pone.0017922.g001
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were co-cultured in decreasing amounts with fully allogeneic
Peripheral Blood Mononuclear Cells (PBMC) containing allor-
eactive T-cells. When added during the MLR reaction, IL-8 did
not change the proliferation of T cells (Figure 3A) or the ensuing
production of INF-c to the supernatant (data not shown).
DC were derived from CD14
+ monocytes in the presence of
GM-CSF and IL-4 and during this process we had observed that
tumor-derived compounds impair differentiation [26]. However,
in the case of IL-8 as a recombinant protein, resulting DC
stimulated allogenic MLRs as strongly as those DC derived in the
absence of the IL-8 chemokine (Figure 3B).
Alternatively, IL-8 could alter the maturation/activation of DC
[29]. To induce maturation, DC were incubated for 48 h with a
mixture of INF-a, TNF-a and Poly I:C in the presence or absence
of IL-8. No change was observed again in the ability of DC to
induce proliferation of allogeneic T lymphocytes (Figure 3C). To
rule out alterations of the recombinant protein used, in every case,
IL-8 was controlled for functionality since it readily attracted
human neutrophils, as shown in chemotaxis assays (Figure S4).
We had previously shown that DC expressed CXCR1 and
CXCR2 [1]. We observed that the exposure to the ligand for two
hours induced the modulation/internalization of both receptors
(Figure 3D) in the very same DC used to set up the T-cell
allostimulation experiments. Therefore, the pathways guiding IL-
8-directed migration and those governing the capabilities for T-
cell stimulation seem to be fairly independent in the DC.
The absence of effects on T cell:DC co-cultures suggested that
the molecular factors employed by the DC for T cell activation
were not affected by IL-8.
Figure 2. IL-8 produced by tumor cells in vivo retains DC inside xenografted tumor nodules. (A) HT29 was xenografted into Rag
2/2 IL-
2Rc
2/2 double KO mice. Tumor nodules, 8–12 mm in diameter, were injected with 5610
6 PKH26-labeled monocyte-derived DC. When indicated, the
100 mL DC suspensions contained 100 mg/mL of mouse IgG (control antibody) or anti-IL-8 neutralizing mAb. The figure shows the proportion of
PKH26
+ events with respect to total tumor cells upon FACS analysis, three days after DC injection. Four mice with two bilateral xenografted tumors
each per condition were used. Of note, DC cultured in the presence of the anti-IL-8 mAb at 100 mg/mL did not show loss of viability at least in 72 h
(data not shown). (B) Representative FACS dot plots from A in two tumor nodules from two mice are shown as an example. Similar data were
obtained with xenografts of the CaCo2 cell line (Figure S2). (C) Absence of PKH26-labeled DC in 3 out of 3 SW48 xenografts processed as in A,
following injection of fluorescence labeled human DC. In the left dot-plot, the fluorescence intensity of injected PKH26-labeled DC is shown for
reference. Dot plots are from representative experiment of two actually performed with three animals per group each.
doi:10.1371/journal.pone.0017922.g002
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not alter the level of expression the maturation markers CD80,
CD83, CD86 and MHC class II on mature and immature DC.
Moreover, IL-8 did not alter the production of IL-12 and IL-10
upon maturation as induced by lipopolysaccharide (LPS) plus the
R-848 imidazoquinoline or recombinant CD40L (Figure S5).
Furthermore, we explored the issue of whether immunodeficient
animals bearing IL-8-producing tumors would impair MLR alloreac-
tions of human leukocytes seeded inside their peritoneal cavities. For
this purpose, we grafted HT29 tumors for 5–7 weeks and co-injected
PKH2-labeled PBL and allogeneic DC inside the peritoneal cavity. As
can be seen in figure 4, T cells readily proliferated in tumor-free mice
within 4 days and such proliferative responses were clearly downsized
by the presence of subcutaneous tumors.
If neutralizing anti-IL-8 mAb was co-injected with the PBL and
the allogenic DC, no recovery of proliferation was observed. This
is interpreted in the sense that factors other than IL-8 down-
regulate T-cell proliferation. This is in agreement with the lack of
IL-8 effects on DC-mediated T-cell stimulation in the in vitro
alloreactive co-cultures.
In addition, we performed experiments (shown in figure 4B) that
demonstrate that treatment of the HT29-xenografted mice with
cyclophosphamide did not improve the alloreactive T-cell
stimulation. Moreover SW48 xenografts, that do not produce
IL-8, also inhibit the intraperitoneal alloreactive response to an
extent comparable to that observed with HT29 (Figure 4B).
Regardless the fact that there is no IL-8 homologue gene in the
mouse genome, human IL-8 exerts at least some agonist activity
on mouse CXCR1 as described [6]. Indeed, we were able to
observe IL-8 chemotactic activity on mouse bone marrow-derived
DC (Figure S6A). Therefore we set up experiments in which we
activated CD4
+ TCR-transgenic OT-2 T cells responding to
ovalbumin in the peritoneal cavity of Rag
2/2 IL-2Rc
2/2 mice.
DC were pulsed with the cognate peptide and the mice were
bearing or not established HT29 subcutaneous tumors. As shown
in figures S6B and C, HT29 tumors also suppressed proliferation
of the mouse T cells in this setting, although such an inhibition was
not affected again by IL-8 neutralizing antibodies. Our data
further indicate the existence of immunosuppressive factors in the
tumor bearing mice which are different from IL-8.
Pre-exposure of DC to IL-8 disorient DC to subsequently
follow IL-8-guided migration
DC in tumor bearing subjects would be chronically exposed to
IL-8. As we have shown in figure 3D, exposure of DC to IL-8
determines receptor downregulation. Therefore we hypothesized
that pre-incubation of DC with IL-8 could inhibit subsequent
responses to IL-8 gradients.
In figure 5, chemotactic experiments were set up plating IL-8-
producing HT29 cells in the lower chamber and PKH2-labelled
DC in the upper chamber. The colon carcinoma cell line induced
migration of DC in 16 h that was abolished by anti-IL8
neutralizing mAb. Interestingly, if DC had been pre-exposed for
24 h to recombinant IL-8, migration was also abolished indicating
that desensitized DC could not migrate towards the IL-8-
producing carcinoma cells. Data are quantified in figure 5B,
which also shows that monolayers of the SW48 (the cell line that
does not produce IL-8) also fail to attract DC. Likewise, pre-
treatment of the HT29 cells with low concentrations of
cyclophosphamide decreased the ability of HT29 to attract DC
because of reducing IL-8 secretion (Figure 5C).
Therefore while IL-8 seems to leave T cell stimulation by DC
unimpaired, chronic exposure to IL-8 may profoundly affect the
migration capabilities of DC towards IL-8 gradients and possibly
of other leukocyte subsets as well.
In a previous study we reported that DC produce IL-8 [1].
Figure S7A confirms that DC produce IL-8 at the protein and
mRNA level. It was conceivable the autocrine IL-8 may
downregulate CXCR1 and CXCR2 expression, as seen in
figure 3D with exogenously added IL-8. Indeed, we observed
brighter immunofluorescence specific for CXCR1 and CXCR2
when IL-8 was neutralized with a specific mAb (Figures S7B and
C) and when DC were cultured at very low cell densities upon
agitation to dilute the secreted IL-8 (Figures S7B, C and D).
Therefore autocrine IL-8 determines the level of receptor surface
expression in DC providing an interesting mode of regulation.
IL-8 produced by DC retains and attracts neutrophils
A function of IL-8 could be to favor a rendezvous between
polymorphonuclear (PMN) cells and DC by co-attracting both
subsets of leukocytes. In our hands, both immature and mature
DC produce abundant IL-8, although mature DC produce about
four-five-fold more quantity on a per cell basis (Figure S7).
Classical chemotaxis assays were set up to determine if IL8
could regulate DC and PMN migration in a concerted fashion. As
can be seen in figure 6A and figure S4, neutrophils are attracted by
recombinant IL-8. However, if neutrophils are seeded together
with DC (at 1:1 ratio), neutrophil migration as induced by IL-8
was abolished. These data might indicate that DC have a means to
attract and/or retain PMNs that otherwise would migrate away.
If the assays were set up with PMNs in the upper and DC in the
lower chamber, neutrophils were attracted by DC seeded into the
lower chamber. Importantly, addition of neutralizing anti-IL-8
mAb eliminated most of the attraction of fluorescence-labeled
neutrophils by the DC seeded in the lower chamber (Figure 6B)
while control antibody exerted no effect.
Our results as a whole indicate that although IL-8, abundantly
produced by tumors, would not damage DC-mediated stimulation
of T-cells. However, tumor-derived IL-8 would alter migration
and interactions with other leukocyte subtypes such as neutrophils.
For instance, if DC are prevented from migrating towards MIP3a
gradients by HT29 supernatants they would reach the inflamma-
Figure 3. IL-8 does not impair T cell stimulation by DC that express functional CXCR1 and CXCR2. (A) Human monocyte-derived DC and
T-cells were seeded in the indicated proportions. Functional recombinant IL-8 was added at different concentrations as indicated in the graph
legends. T-cell proliferation was measured by
3H-thymidine incorporation 3 days later. A representative case out of three independently performed
experiments with cells from different combinations of donors is shown. (B) Experiments as in A, but in this case DC were incubated with the indicated
amounts of IL-8 added to monocytes during the 7-day differentiation culture in the presence of GM-CSF+IL-4. A representative experiment out of at
least three is shown. (C) Similar experiments as in B but in this case IL-8 at the indicated concentrations was added during the maturation 48 h culture
onto differentiated DC matured for 48 h with IFN-a, TNF-a and poly I:C. A representative experiment out of at least three performed is shown. As a
control every IL-8 batch was shown to readily attract human PMNs in chemotaxis assays (Figure S3). (D) Mature DC as those used for the MLRs were
tested by indirect immunofluorescence for the expression of CXCR1 and CXCR2. Incubation with 100 ng/mL of IL-8 during 2 h resulted in a loss of
fluorescence intensity upon immunostaining of the surface receptors indicating receptor internalization. The mean fluorescence intensity (MFI) of
each histogram is provided. FACS Experiments were repeated in two occasions with similar results.
doi:10.1371/journal.pone.0017922.g003
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less efficiently (Figure S8). IL-8-disoriented migration could
thereby contribute to weaken immune responses to cancer.
IL-8 produced by tumor xenografts attracts DC to the
tumor tissue unless they have been desensitized by pre-
exposure to IL-8
As seen in figure 1, HT29 xenografts are sites of intense IL-8
production. Therefore we reasoned that DC injected in the
subcutaneous tissue 5 mm away from the tumor (Figure 7A)
should be attracted to the tumor nodule. Indeed, fluorescence-
labelled DC were recovered from the tumor tissue and such
migratory behaviour was inhibited if DC were co-injected with the
neutralizing anti-IL-8 mAb (Figure 7B). More importantly, pre-
exposure of the DC cultures to IL-8 for 24 h prior to injection also
greatly impaired the migration towards the tumor. Therefore
tumors can attract DC by means of IL-8 but chronic exposure to
IL-8 desensitizes DC for this in vivo migration. Owing to these
effects, IL-8 produced at malignant lesions profoundly impairs the
migratory orientation of DC.
Figure 4. Impairment of DC-induced human T-cell proliferation inside the peritoneum of HT29 xenografted mice. (A) Rag
2/2IL-2cR
2/2
mice (3 per group) were xenografted with HT29 cells or remained tumor-free. Four weeks later mice received intraperitoneal injections of human PKH2-
labeled PBLs and fully allogenic mature DC (ratio 5:1 to a total of 6610
6 cells). Proliferation was monitored four days later by dye dilution on FACS-gated
lymphocytes from peritoneal lavages by dilution of the fluorescent dye. In the group of indicated mice an intraperitoneal injection of 100 mg of neutralizing
anti-IL-8 mAb was provided immediately following the injectionofPBLs and DC. Percentages of dividing lymphocytes in eachlog cursorinterval areshown
inthehistograms.FluorescenceintensityintheinputundividedPBLwasover95%abovethethirdloginterval(upperhistogram).(B)Similarexperiments as
in A, quantifying PKH2-dilution as thepercentage of cells that reachthe 3
rd and 4
th log scales of the flow cytometry histograms. Log regions are depicted in
the upper histogram of A. Data from animals bearing subcutaneous SW48 xenografts, that do not produce IL-8, have been included. Data represent
mean6SD.
doi:10.1371/journal.pone.0017922.g004
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By producing IL-8, tumors may profoundly alter the migration-
guiding gradients of this important chemokine in the tissues of
tumor-bearing hosts [33]. Indeed, the chemokine network is well
known to modify cancer biology in multiple ways from metastasis
and angiogenesis to the attraction of a nurturing leukocyte
infiltrates [33]. In this study, we demonstrate that IL-8 as
produced by human tumor cells is capable of attracting (or
retaining) human DC in vivo, but that IL-8 does not functionally
affect the ability of DC to stimulate alloreactive T cells.
We found that at least in vitro, IL-8 production by tumor cells
can be decreased by low dose cyclophosphamide at the protein
and mRNA level. In vivo this is reflected by transient decreases in
the serum concentration of the chemokine in circulating blood.
The rapid decrease and recovery of serum concentrations indicate
the rapid turnover in blood of a polypeptide below the renal
filtration threshold and with a short half-life [34]. We are
exploring the therapeutic implications of low-dose cyclophospha-
mide effects on IL-8 patho-phisiology. In fact, this effects on IL-8
output can be a factor behind the beneficial effects of the described
metronomic dosing of the drug [31,32]. In addition acute
reductions in IL-8 output as induced by cyclophosphamide might
be exploited to support intratumoral injections of DC in order to
favor migration to lymph nodes.
In a clinical trial IL-8 was suspected to mediate intratumoral
retention of DC artificially delivered in such locations by image-
guided procedures of injection [1]. However, the role of IL-8 at in
Figure 5. DC pre-exposed to IL-8 become desensitized to respond to carcinoma-derived IL-8 as a chemoattractant. (A) Chemotaxis
assays were set up with HT29 confluent monolayers in the lower chamber and fluorescent DC in the upper chamber. Phase contrast microscopy
images and the corresponding UV fluorescence microscopic fields of the lower chamber are shown. When indicated the lower chamber contained
neutralizing anti-IL-8 mAb (20 mg/mL) or the DC had been pre-exposed for 24 h to recombinant IL-8 (1 mg/mL). (B) In the upper panel representation
of data from three independent experiments similarly performed to those in A with HT29 cells represented as mean6SD in which four random fields
were counted for each triplicate well. In the lower panel experiments performed as in A, but in this case the confluent monolayers in the lower
chamber were formed by SW48 cells that do not produce IL-8. (C) Experiments as in A, but in this case HT29 cells had been pretreated with various
cyclophosphamide concentrations for 24 h as indicated in the figure. Results represent mean6SD.
doi:10.1371/journal.pone.0017922.g005
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study, we observe that DC are retained inside xenografted colon
carcinomas by IL-8. The evidence was generated by means of a
neutralizing anti-IL-8 mAb injected alongside the DC. These
findings further support our interpretations with regard to the
apparent retention of intratumorally injected DC in patients
according to scintigraphic scans [1,2].
In our mouse xenograft system, we do not yet understand
whether migration out of tumors is the result of chemotaxis driven
by mouse factors or random migration. What we document is that
IL-8 mediates the retention inside the tumor microenvironment.
This is not a surprise since IL-8 receptors, CXCR1 and CXCR2,
are expressed on DC and are functional in classical chemotaxis
assays [1]. The production of IL-8 by DC themselves could be also
operating in an autocrine or paracrine fashion in this intratumoral
setting. Nonetheless, we clearly observe that HT29 tumor
xenografts are capable to chemoattract DC when injected in the
connective tissue that surrounds the malignancy.
Figure 6. DCs retain neutrophils in migration assays towards IL-8 and attract neutrophils in an IL-8-dependent fashion. (A) Transwell
chemotaxis assays were set up with PKH2-labeled neutrophils. Neutrophils migrated to recombinant IL-8 added to the lower chamber. However, if
neutrophils are seeded in the upper chamber together with DC (1:1) migration is totally impaired. Of note there is IL-8 by the DC as shown in figure
S6A. This experiment is representative of two independently performed in triplicate wells with migration lasting for 120 min. (B) Percentage of
migration of PKH2-labeled neutrophils that were seeded into the upper chamber of transwell migration assays towards recombinant IL-8 or DC
placed in the lower chamber. When indicated, IL-8-neutralizing mAb (20 mg/mL) was added to the lower chamber along with the DC. Migration was
analyzed at 120 minutes. Similar experiments analyzed as early as 60 minutes rendered similar results (data not shown). Results are representative of
two separate triplicate experiments independently performed. Asterisks indicate statistical significance p,0.01 in student’s t tests.
doi:10.1371/journal.pone.0017922.g006
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pathways [35] and rearrange the cytoskeleton [13]. IL-8 could
thereby potentially alter the functional performance of DC.
Therefore we hypothesized that DC under the influence of IL-8
in the tumor, would be poorer T cell stimulators. However, fully
functional IL-8 (as checked in migration assays) was completely
incapable of decreasing T-cell allostimulation as mediated by DC.
This is in agreement with the fact that IL-8 does not affect the
expression of costimulatory receptors or T-cell stimulating
cytokines. It remains to be seen if IL-8 alters the antigen
Figure 7. HT29 xenografts attract human DC injected in the subcutaneous tissue which surrounds the tumor. (A) Mice bearing HT29
established xenografts as the one shown in the pictures were injected approximately 5 mm away from the tumor lesion with 5610
6 human
immature DC labelled with PKH2 that were resuspended in 50 ml of saline buffer to form a small subcutaneous bump which disappeared in less than
2 hours. (B) 24 hours later tumors were surgically removed and a cell suspension was obtained in which the number of fluorescent DC were
enumerated by flow cytometry and normalized as the percentage of injected DC that were recovered from the tumor. When indicated DC were pre-
treated for 24 hours in culture with 1 mg/ml of rIL-8 or DC were co-injected with 100 mg of neutralizing anti-IL8 mAb.
doi:10.1371/journal.pone.0017922.g007
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not required for alloreactive stimulation. Although not formally
ruled out, this possibility is considered unlikely.
Nonetheless, if DC were retained in the tumor milieu by IL-8,
those DC would remain under the concentrated influence of
tumor-derived factors that repress DC functions [26,36,37,38].
Evidence for this phenomenon also comes out from our
alloreactive reactions of human lymphocytes inside the peritone-
um of immunodeficient mice bearing HT29 and SW48 xenografts
[39]. Some of the malignant tissue immunorepressor molecules
include TGF-b [40,41], VEGF [42,43], interleukin-13 [44],
prostaglandins, kynurerines [40] and most likely other unknown
polypeptide moieties [26], as well as certain lipids [45].
Collectively, our data can be interpreted in the sense that IL-8
retains DC in the precise location where such antigen presenting
cells are most efficiently damaged in their function by tumor-
derived biomolecules. Our results regarding the in vivo inhibition of
T-cell allostimulation in animals xenografted with human tumors
offer a useful experimental system to dissect tumor-dependent
mechanisms of inhibition that are operating distantly from the
tumor implant. This experimental tool is employed in our
laboratory [39].
DC intratumoral retention has been described as an evasion
strategy in breast cancers [46]. We can observe in in vitro
chemotaxis that if HT29 cells prevent DC from migrating to
MIP3a mimicking an inflammatory focus then fewer DC reach
the location to stimulate T cells and the immune response is
accordingly less intense.
These phenomena certainly pose an obstacle for the intratu-
moral route of DC administration in human immunotherapy [11],
an approach that has been described to be very successful in a
number mouse models [47,48,49,50]. From the therapeutic point
of view, low doses of cyclophosphamide can be useful to reduce IL-
8 output by viable tumor cells. Neutralization of IL-8 with mAb
could be also therapeutically feasible. This has been recently
demonstrated in a situation in which tumor xenografts escape
from sunitinib-induced anti-angiogenesis by means of an IL-8-
dependent mechanism [19].
IL-8 attracts neutrophils and possibly immature forms such as
myeloid derived suppressor cells [37,51]. Interestingly, DC secrete
IL-8 that may act in an autocrine fashion [1]. Apart from these
largely unexplored autocrine effects that modulate CXCR1 and
CXCR2 surface levels; we show that DC are capable of attracting
or retaining neutrophils in an IL-8-dependent fashion. The
physiological consequences of DC-neutrophil interactions [52] in
the tumor context are currently being actively explored in our
laboratory, with emphasis on the implications for cross-presenta-
tion of tumor antigens [53,54].
What seems also plausible is that under high circulating levels of
IL-8, as occurs in HT29-xenografted mice or patients with bulky
disease, migration-driving gradients of IL-8 would be disrupted
and thereby DC-production of IL-8 might be overwhelmed in its
ability to attract neutrophils and other leukocytes. Indeed, we have
obtained evidence in the sense that overwhelming pre-exposure to
IL-8 results in desensitization of the DC to the chemotactic effects
of IL-8. In other words, this could mean that DC chronically
exposed to IL-8 in the context of tumor-bearing hosts would
become disoriented and thus unable to follow migration cues set
up by IL-8 concentration gradients. In vivo evidence of desensiti-
zation for migration further supports this notion. Such immune
disorientation as caused by the abundantly and ectopically
expressed chemokine may result in disordered immune responses
and ought to have relevant prognostic consequences for patients.
Supporting Information
Figure S1 Colon carcinoma cell lines HT29 and CaCo2
produce high levels of IL-8 in a clonal stable fashion
while SW48 does not produce IL-8. Clonal limiting dilution
subcultures (four for each cell line) of the colon cancer-derived cell
lines HT29, CaCo2 and SW48 were tested for the production of
IL-8 as measured in 24 h culture supernatants by ELISA.
(TIF)
Figure S2 CaCo2 carcinoma cells xenografted in immu-
nodeficient mice develop progressive intraperitoneal
tumors that correlate with raising serum concentrations
of IL-8. Intraperitoneally xenografted CaCo2 cells developed
progressive peritoneal colon carcinomas in athymic nude mice
(measured as weight increase in the left axis) and accumulated
increasing concentrations of serum IL-8 (right axis).
(TIF)
Figure S3 DC are retained inside CaCo2 tumors in a IL-
8-dependent fashion. CaCo2 cells were xenografted in athymic
nude mice. Only 1/3 of such animals successfully xenografted
tumor lesions. Tumor nodules, 8–12 mm in diameter, were
injected with CFSE-labeled human DC derived from monocytes,
as in A. DC were injected in 100 mL of saline buffer with control
antibody or neutralizing anti-IL-8 mAb. In these cases, tumors
were homogenated and cleared of debris by centrifugation.
Fluorescence in the lysate was measured in a fluorimeter. The
amount of fluorescence remaining in the tumor compared to that
present in the lysate from an identical number of DC before being
injected in the tumor was quantitated. Data are presented as the
percentage of fluorescence lost from the tumor. Experiments were
performed with four mice bearing a single tumor nodule. The inset
shows a correlation of fluorescence (arbitrary units) and number of
DC in lysates containing increasing amounts of CFSE-labeled DC.
(TIF)
Figure S4 Recombinant IL-8 rendering negative results
at modifying DC functionality is capable of attracting
PMNs. Migration transwell assays with purified neutrophils in the
upper chamber and different concentrations of the recombinant
IL-8 in the lower chamber to prove that IL-8 used in figure 3A, B,
C and D was fully functional.
(TIF)
Figure S5 IL-8 does not modify IL-12 nor IL-10 secretion
by DC matured in the presence of LPS+R848 or
trimerized CD40L. IL-12 and IL-10 were quantified in the
supernatant of DC cultures treated with the indicated concentra-
tions of IL-8 during the 48 h maturation culture. Concentrations
(mean6SD) represent triplicate wells from a single experiment.
(TIF)
Figure S6 Activation of antigen specific murine CD4 T
cells by DC in mice bearing HT29 tumors is suppressed
by factors distinct from IL-8. (A) Mouse BM-derived DC
[50,55] were subjected to classical transwell chemotaxis assays
towards culture medium (control), 10
5 heat-inactivated E. coli
bacteria used as a positive control, or recombinant IL-8 as
indicated. Data show a modest but reproducible attraction of
mouse DC by human recombinant IL-8. (B) Schematic represen-
tation of experiments in which HT29-bearing Rag
2/2 IL-2Rc
2/2
mice were injected in the peritoneal cavity with 5610
6 CFSE-
labelled CD4 OT-2 cells [56] and 10
6 syngeneic DC pulsed with
the OVA323-339 synthetic peptide. (C) Assessment of OT-2 T-cell
proliferation by dilution of CFSE as in figure 4. Experiments were
performed in mice bearing or not HT29 tumors with or without
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When indicated 100 mg of anti-IL8 mAb were co-injected into the
peritoneal cavity.
(TIF)
Figure S7 DC produce IL-8 and such autocrine IL-8
modulates in part the surface expression of CXCR1 and
CXCR2. (A) Left axis: IL-8 concentration in the supernatant of
mature (mDC) and immature DC (iDC); Right axis: mRNA
encoding IL-8 in the corresponding DC cultures assessed by semi
quantitative RT-PCR. (B and C) IL-8 concentration in the
supernatant (left axes) and CXCR1 (B) and CXCR2 (C) surface
expression as mean fluorescence intensity (MFI) analyzed by
FACS (right axes). In B and C a mAb neutralising IL-8 (20 mg/ml)
was added when indicated, or the DC were cultured under gentle
agitation at the cellular densities given. Results are presented as
mean6SD from triplicate experiments. IL-8 neutralisation or
lower IL8 concentrations in the supernatants correlate with higher
MFIs for CXCR1 and CXCR2 on the DC. (D) Shows
representative FACS histograms from B and C.
(TIF)
Figure S8 IL-8 in conditioned supernatants from HT29
cells impedes DC from migrating to MIP3a gradients. As
a consequence fewer DC reaching the lower chamber results in
less T-cell allostimulatory activity at this location. In order to
model whether DC-disoriented migration would give rise to less T
cell stimulation, we set up in the left panel chemotaxis assays in
which DC migrated towards recombinant MIP3a (100 mg/ml).
Data are presented as mean6SD of the chemotactic index
normalized with culture medium without MIP3a (Neg). DC were
seeded in the upper chamber with or without conditioned medium
of HT29 cells or SW48 cells as indicated. When indicated an IL-8
neutralising antibody was added. In the right panel DC recovered
from the lower chamber were used to stimulate allogenic PBL, and
T-cell proliferation was recorded three days later as c.p.m. in
3H-Thy incorporation assays. Data represent three independent
replicates.
(TIF)
Table S1 Lack of IL-8 effect on surface expression of
dendritic cell maturation markers. Mean fluorescence
intensity of the indicated surface markers of DC upon FACS
analyses in human DC (mean6SD from three different experi-
ments) using either immature (iDC) or LPS+R848 matured DC
(mDC), that were cultured in the absence or the presence of
increasing concentrations of IL-8 as indicated in the columns.
Experiments are representative of three similarly performed with
different donors.
(TIF)
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